Peripheral cholinergic disturbances in Alzheimer's disease

被引:25
|
作者
Rakonczay, Z [1 ]
Horváth, Z
Juhász, A
Kálmán, J
机构
[1] Univ Szeged, Alzheimers Dis Res Ctr, Dept Oral Biol, Szeged, Hungary
[2] Univ Szeged, Fac Med, Dept Psychiat, H-6720 Szeged, Hungary
关键词
Alzheimer's disease; acetylcholinesterase; butyrylcholinesterase; molecular forms; apolipoprotein E; butyrylcholinesterase K variant;
D O I
10.1016/j.cbi.2005.10.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most pronounced neurochemical abnormality in Alzheimer's disease (AD) is cholinergic dysfunction in the central nervous system. Peripheral tissues may also be affected, however, including blood. The present study undertook to determine the activity of acetylcholinesterase (AChE) and its molecular forms in erythrocytes, lymphocytes and platelets of normal elderly subjects and probable AD cases. These samples contained dimeric globular (G2), tetrameric globular (G4) and asymmetric (A12) AChE forms, but no globular monomeric (G1) enzyme. In both lymphocytes and platelets, the major AChE molecular form was G2 (approximately 80%), with G4 and A12 forms accounting for nearly equal portions of the remainder. Total AChE activities and measured sedimentation coefficients were similar in the control and AD samples (from patients with mild and moderately severe cognitive deficiency). However, the groups differed significantly in the proportion of certain AChE molecular forms. Thus, as compared with controls, the amount of A 12 AChE in the AD samples was increased 148 and 161% in lymphocytes and platelets, respectively. Genotyping for apolipoprotein E (ApoE) and the butyrylcholinesterase K (BCHE-K) variant, carried out using the polymerase chain reaction, showed that AD patients carried the ApoE4 allele at a significantly higher frequency than the controls. On the other hand there were no significant group differences in the occurrence of the BCHE-K variant and no synergism between ApoE alleles and the BCHE-K variant in our Hungarian AD population. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 50 条
  • [21] Update on cholinergic drugs in Alzheimer's disease
    Kumar, V
    Sugaya, K
    Saunders, S
    Mechanic, J
    DRUGS OF TODAY, 1996, 32 (07): : 529 - 537
  • [22] Nicotinic Cholinergic Mechanisms in Alzheimer's Disease
    Shen, Jianxin
    Wu, Jie
    NICOTINE USE IN MENTAL ILLNESS AND NEUROLOGICAL DISORDERS, 2015, 124 : 275 - 292
  • [23] Alzheimer's disease - Cholinergic therapy and beyond
    Sunderland, T
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 1998, 6 (02): : S56 - S63
  • [24] Cholinergic foundations of Alzheimer's disease therapy
    Giacobini, E
    JOURNAL OF PHYSIOLOGY-PARIS, 1998, 92 (3-4) : 283 - 287
  • [25] Alzheimer's Disease: Targeting the Cholinergic System
    Ferreira-Vieira, Talita H.
    Guimaraes, Isabella M.
    Silva, Flavia R.
    Ribeiro, Fabiola M.
    CURRENT NEUROPHARMACOLOGY, 2016, 14 (01) : 101 - 115
  • [26] The Cholinergic Neuronal Phenotype in Alzheimer's Disease
    Jan Krzysztof Blusztajn
    Brygida Berse
    Metabolic Brain Disease, 2000, 15 : 45 - 64
  • [27] The cholinergic neuronal phenotype in alzheimer′s disease
    Jan Krzysztof Blusztajn
    Brygida Berse
    Metabolic Brain Disease, 2000, 15 (1) : 45 - 64
  • [28] Alzheimer's disease: correct the cholinergic deficiency
    Fourcade, M
    PRESSE MEDICALE, 1997, 26 (38): : 1885 - 1885
  • [29] The cholinergic neuronal phenotype in Alzheimer's disease
    Blusztajn, JK
    Berse, B
    METABOLIC BRAIN DISEASE, 2000, 15 (01) : 45 - 64
  • [30] Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit
    Gil-Bea, FJ
    García-Alloza, M
    Domínguez, J
    Marcos, B
    Ramírez, MJ
    NEUROSCIENCE LETTERS, 2005, 375 (01) : 37 - 41